7639-68-1

Usage

Uses

Used in Pharmaceutical Industry:
4,4,4-TRIFLUORO-1-(1-NAPHTHYL)BUTANE-1,3-DIONE is used as a key intermediate in the synthesis of pharmaceuticals for its ability to form complex molecular structures and functional groups.
Used in Agrochemical Industry:
In the agrochemical industry, 4,4,4-TRIFLUORO-1-(1-NAPHTHYL)BUTANE-1,3-DIONE is used as a building block in the development of agrochemicals, contributing to the creation of effective and targeted products.
Used in Materials Science:
4,4,4-TRIFLUORO-1-(1-NAPHTHYL)BUTANE-1,3-DIONE is utilized in materials science applications to engineer novel materials with specific properties, taking advantage of its structural features.
Used as a Fluorescent Probe in Biochemical and Biomedical Research:
4,4,4-TRIFLUORO-1-(1-NAPHTHYL)BUTANE-1,3-DIONE serves as a fluorescent probe in biochemical and biomedical research, allowing for the visualization and tracking of certain processes due to its fluorescence upon ultraviolet light excitation.

Upstream product

• 941-98-0 1'-naphthacetophenone 
• 383-63-1 ethyl trifluoroacetate, 

Downstream Products

• 1177469-45-2 4-(5-naphthalen-1-yl-3-trifluoromethyl-pyrazol-1-yl)-benzenesulfonamide 
• 1252678-95-7 5-Naphthalen-1-yl-1-(4-nitro-phenyl)-3-trifluoromethyl-1H-pyrazole 
• 1177469-53-2 4-(5-naphthalen-1-yl-3-trifluoromethyl-pyrazol-1-yl)-phenylamine 

Relevant academic research and scientific papers

Bright Yb3+ complexes for efficient pure near-infrared OLEDs

A series of neutral Yb3+ and Gd3+ complexes with isomeric 4,4,4-trifluoro-1-(naphthalenyl)butane-1,3-diones and 1,10-phenanthroline as an ancillary ligand were synthesized and characterized by a full range of analytical methods, including elemental analysis, FTIR and NMR spectroscopy, single crystal X-ray analysis, cyclic voltammetry (CVA) and thermal analysis (TG/DTA). Moreover, the unexpected formation of a mixed diketonate-carboxylate Yb3+ complex [Yb(2-Naph)2(CF3COO)(phen)(H2O)] from [Yb(2-Naph)3(phen)] in solution was observed. The photoluminescence quantum yield (PLQY) for complex [Yb(2-Naph)3(phen)] in the near infra-red region (one band with a peak at 980 nm) was about 3,2%. This value is close to the highest one reported for 1,3-diketonate complexes of Yb3+ ion to date. The energy transfer process is discussed in details, based on the results of TD-DFT calculations and experimental photophysical measurements. These complexes were successfully used as emitters in multilayer OLEDs. The electroluminescence quantum efficiency corresponding to the sole band at 980 nm reached 0.042% with a maximum irradiance of 11 μW/cm2 at 8.5 V for [Yb(2-Naph)3(phen)] based device, which is unusually high for such type of emitters.

Stereoarrayed CF3-Substituted 1,3-Diols by Dynamic Kinetic Resolution: Ruthenium(II)-Catalyzed Asymmetric Transfer Hydrogenation

CF3-substituted 1,3-diols were stereoselectively prepared in excellent enantiopurity and high yield from CF3-substituted diketones by using an ansa-ruthenium(II)-catalyzed asymmetric transfer hydrogenation in formic acid/triethylamine. The intermediate mono-reduced alcohol was also obtained in very high enantiopurity by applying milder reaction conditions. In particular, CF3C(O)-substituted benzofused cyclic ketones underwent either a single or a double dynamic kinetic resolution during their reduction. Doubling up: A double dynamic kinetic resolution is described for the ansa-ruthenium(II)-catalyzed asymmetric transfer hydrogenation of diketones in formic acid/triethylamine to yield the title compounds, displaying a stereotriad, in excellent stereopurity. The intermediate mono-reduced alcohols were isolated in very high enantiopurity by using milder reaction conditions.

Development of novel antibacterial agents against methicillin-resistant Staphylococcus aureus

Methicillin-resistant Staphylococcus aureus (MRSA) poses a serious threat to public health because of its resistance to multiple antibiotics most commonly used to treat infection. In this study, we report the unique ability of the cyclooxygenase-2 (COX-2) inhibitor celecoxib to kill Staphylococcus aureus and MRSA with modest potency. We hypothesize that the anti-Staphylococcus activity of celecoxib could be pharmacologically exploited to develop novel anti-MRSA agents with a distinct mechanism. Examination of an in-house, celecoxib-based focused compound library in conjunction with structural modifications led to the identification of compound 46 as the lead agent with high antibacterial potency against a panel of Staphylococcus pathogens and different strains of MRSA. Moreover, this killing effect is bacteria-specific, as human cancer cells are resistant to 46. In addition, a single intraperitoneal administration of compound 46 at 30 mg/kg improved the survival of MRSA-infected C57BL/6 mice. In light of its high potency in eradicating MRSA in vitro and its in vivo activity, compound 46 and its analogues warrant continued preclinical development as a potential therapeutic intervention against MRSA.